1529 Treffer:
51.
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
52.
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumo
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
53.
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors.
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
54.
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Me
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
55.
Cancer Organoids as Platform to Personalized Radiation Oncology
NCT Heidelberg » Für Ärzte » Studien » Sarkome » Weichteilsarkome
Datum: 2026-05-09
56.
IMPULS-A: Implementierung eines Unterstützungsprogramms für Langzeitkrebsüberlebende im Alter
NCT Heidelberg » Für Ärzte » Studien » Sarkome » Weichteilsarkome
Datum: 2026-05-09
57.
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with advanced or metastatic NSCLC in Germany
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
58.
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT Heidelberg » Für Ärzte » Studien » Thorakale Tumoren » Bronchialkarzinom
Datum: 2026-05-09
59.
Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)
NCT Heidelberg » Für Ärzte » Studien » Sarkome » Weichteilsarkome
Datum: 2026-05-09
60.
Pragmatische Studie der Verkleinerung von Tumoren mittels klassischer und räumlich fraktionierter Bestrahlung (SHRINK)
NCT Heidelberg » Für Ärzte » Studien » Sarkome » Weichteilsarkome
Datum: 2026-05-09